CONTACT
+91 80 2808 2808
ContactUs.BBL@biocon.com

Resubmission of Biosimilar Trastuzumab and Pegfilgrastim Dossiers with EMA

  • Posted by: Biocon Biologics

Bengaluru, Karnataka, India, November 7, 2017:

Biocon´s partner Mylan has resubmitted the Marketing Authorization Applications (MAAs) for our proposed biosimilar trastuzumab and pegfilgrastim with the European Medicines Agency (EMA) as per the administrative protocol. This follows the earlier withdrawal of both applications in response to the audit of our aseptic drug product facility by the designated European authority. Biocon has completed the Corrective and Preventive Actions (CAPAs), including the facility modifications, in response to the audit observations and expects these to be verified during re-inspection.

Author: Biocon Biologics
Share